Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 is effective in vitro and in vivo in Multiple Myeloma

被引：0
|
作者：
Perumal, Deepak [1 ]
Thirukonda, Venu [2 ]
Jiang, Zewei [3 ]
Leshchenko, Violetta V. [1 ]
Kuo, Pei-Yu [1 ]
Shahnaz, Samira [4 ]
Rubel, Jennifer [1 ]
Zhang, Weijia [1 ]
Cho, Hearn Jay [1 ]
Reddy, M. V. Ramana [1 ]
Reddy, E. Premkumar [1 ]
Parekh, Samir [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Billings Clin Canc Ctr, Billings, MT USA
[3] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10467 USA
[4] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1324
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1324
引用
收藏
页数：2
相关论文
共 37 条
  • [21] Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)
    Podar, Klaus
    Raab, Marc S.
    Zhang, Jing
    McMillin, Douglas
    Breitkreutz, Iris
    Tai, Yu-Tzu
    Lin, Boris K.
    Munshi, Nikhil
    Hideshima, Teru
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2007, 109 (04) : 1669 - 1677
  • [22] Targeting PKC in multiple myeloma:: In vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCI).
    Raab, Marc S.
    Podar, Klaus
    Zhang, Jing
    McMillin, Douglas
    Breitkreutz, Iris
    Tai, Yu-Tzu
    Lin, Boris
    Ghobrial, Irene
    Munshi, Nikhil
    Hideshima, Teru
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2006, 108 (11) : 989A - 989A
  • [23] A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma
    Niesvizky, Ruben
    Ely, Scott
    Jayabalan, David S.
    Manco, Megan C.
    Singhal, Seema
    Crann, Mary
    Courtney, Rachel
    DuFresne, Cynthia
    Wilner, Keith D.
    Chen, Isan
    Mark, Tomer
    Leonard, John P.
    Coleman, Morton
    DiLiberto, Maurizio
    Huang, Xiangao
    Chen-Kiang, Selina
    BLOOD, 2009, 114 (22) : 745 - 745
  • [24] A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo
    Tang, Juan
    Zhu, Jingyu
    Yu, Yang
    Zhang, Zubin
    Chen, Guodong
    Zhou, Xiumin
    Qiao, Chunhua
    Hou, Tingjun
    Mao, Xinliang
    ONCOTARGET, 2014, 5 (11) : 3836 - 3848
  • [25] The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, and the CDK4/6 inhibitors palbociclib or abemaciclib synergistically enhance each other's in vitro and in vivo anticancer activity
    Annis, A.
    Carvajal, L. A.
    Ren, J-G
    Sutton, D.
    Santiago, S.
    Narasimhan, N.
    Guerlavais, V.
    Aivado, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [26] Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
    E Morelli
    E Leone
    M E Gallo Cantafio
    M T Di Martino
    N Amodio
    L Biamonte
    A Gullà
    U Foresta
    M R Pitari
    C Botta
    M Rossi
    A Neri
    N C Munshi
    K C Anderson
    P Tagliaferri
    P Tassone
    Leukemia, 2015, 29 : 2173 - 2183
  • [27] Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
    Morelli, E.
    Leone, E.
    Cantafio, M. E. Gallo
    Di Martino, M. T.
    Amodio, N.
    Biamonte, L.
    Gulla, A.
    Foresta, U.
    Pitari, M. R.
    Botta, C.
    Rossi, M.
    Neri, A.
    Munshi, N. C.
    Anderson, K. C.
    Tagliaferri, P.
    Tassone, P.
    LEUKEMIA, 2015, 29 (11) : 2173 - 2183
  • [28] The Novel Aurora Kinase Inhibitor ENNM-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo, and Shows Synergistic Activity in Combination with Lenalidomide
    Wang, Xiaojing
    Sinn, Anthony L.
    Suvannasankha, Attaya
    Crean, Colin D.
    Chen, Li
    Zhang, Shuhong
    Liang, Jing
    Zhang, Genglin
    Pollok, Karen E.
    Abonour, Rafat
    Sidor, Carolyn
    Bray, Mark R.
    Farag, Sherif S.
    BLOOD, 2008, 112 (11) : 1253 - 1253
  • [29] The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro
    Prada, Elke Tatjana Aristizabal
    Noelting, Svenja
    Spoettl, Gerald
    Maurer, Julian
    Auernhammer, Christoph Josef
    NEUROENDOCRINOLOGY, 2018, 106 (01) : 58 - 73
  • [30] Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer
    Chen, Xiaoyu
    Shu, Chengxia
    Li, Wenqiang
    Hou, Qiangqiang
    Luo, Guangmei
    Yang, Kexin
    Wu, Xiaoxing
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (09) : 6729 - 6747
1234